Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cross Country Healthcare (CCRN) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cross Country Healthcare (CCRN) over the last 17 years, with Q3 2025 value amounting to $99.1 million.

  • Cross Country Healthcare's Cash & Equivalents rose 5484.29% to $99.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.1 million, marking a year-over-year increase of 5484.29%. This contributed to the annual value of $81.6 million for FY2024, which is 37755.35% up from last year.
  • According to the latest figures from Q3 2025, Cross Country Healthcare's Cash & Equivalents is $99.1 million, which was up 5484.29% from $81.2 million recorded in Q2 2025.
  • In the past 5 years, Cross Country Healthcare's Cash & Equivalents ranged from a high of $99.1 million in Q3 2025 and a low of $279000.0 during Q2 2022
  • Moreover, its 5-year median value for Cash & Equivalents was $14.3 million (2023), whereas its average is $30.7 million.
  • As far as peak fluctuations go, Cross Country Healthcare's Cash & Equivalents plummeted by 9846.09% in 2022, and later skyrocketed by 1024190.19% in 2024.
  • Over the past 5 years, Cross Country Healthcare's Cash & Equivalents (Quarter) stood at $1.0 million in 2021, then skyrocketed by 247.88% to $3.6 million in 2022, then surged by 374.31% to $17.1 million in 2023, then soared by 377.55% to $81.6 million in 2024, then rose by 21.44% to $99.1 million in 2025.
  • Its Cash & Equivalents was $99.1 million in Q3 2025, compared to $81.2 million in Q2 2025 and $80.7 million in Q1 2025.